

5'-GCAAGCATCCCCATCTCCAC-3' (SEQ ID NO: 6) yielding a 550 bp piece.

Amplification conditions for exons 1 and 4 were 40 cycles consisting of a denaturing step at 95°C, an annealing step at 60°C and an extension step at 72°C for 45 seconds each step with 1.5 mM MgCl₂. Exon 6 differed both in the annealing temperature which was 65°C and MgCl₂ concentration which was raised to 2mM. All PCR's utilized Taq Polymerase (Life Technologies, Grand Island, NY), PCR buffer of 20 mM Tris-HCl (pH 8.4) and 50 mM KCl and were carried out using a Perkin Elmer DNA Thermal Cycler 480 (PE Applied Biosystems, Foster City, CA). The products were run on 1.5% agarose gels and treated as a southern hybridization following the above protocol to confirm specificity of the product.

Please delete paragraph [0044] and replace it with the following paragraph:

[0044] Reverse transcription was carried out on 2 µg of total RNA from DU-145, PC-3, LNCaP, and TSU-pr1 cell lines and 1 µg of total RNA from the A875 cell line for 15 minutes at 42°C using 2.5 units reverse transcriptase (Life Technologies, Grand Island, NY) per RNA sample in 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 10 mM DTT, 3 mM MgCl₂. The resulting reverse transcription reaction was subjected to PCR amplification using primers adapted from Schenone et al. (1996). These primers are forward primer 5'-AGCCCCCAATTTCAGTCCGCAAA-3' (SEQ ID NO: 7) and reverse primer 5'-CAGCAGCCAGGATGGAGCAATAG-3' (SEQ ID NO: 8) which amplifies a 847 bp piece. Amplification was carried out through 45 cycles of denaturation at 95°C for 60 seconds, followed by annealing-extension at 60°C for 45 seconds in 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl₂. The resulting amplification reaction of the prostate tumor cell lines were precipitated by addition of 3M sodium acetate and 100% isopropanol at -20°C overnight. The precipitates were then electrophoresed on a 1% agarose gel with a 100-fold dilution of the A875 cell line amplification reaction used as a positive control. Southern hybridization, following the above protocol, was then carried out to confirm specificity of the product.

II. REMARKS

A. The Amendment

In order to comply with sequence listing requirements, the applicants have amended the specification to include a Sequence Listing. The Sequence Listing is presented on separately